

DEC 01 2006

Appl. No. 08/870,762  
Docket No.: 226/104 US  
Page 3AMENDMENTS TO THE CLAIMS

Please enter the following amendments without prejudice or disclaimer.

This listing of claims will replace all prior versions, and listings, of claims in the application.

**In the claims:**

1. (Currently Amended) A method of treating obesity in a human subject in need thereof, said method consisting of comprising administering to said subject an effective amount of a composition comprising an anti-obesity obesity relief agent consisting of an amylin or an amylin agonist and a pharmaceutically acceptable carrier, wherein said amount is effective to treat obesity.
  
2. (Currently Amended) [[A]] The method according to claim 1 wherein said amylin agonist is an amylin agonist analogue.
  
3. (Currently Amended) [[A]] The method according to claim 2 wherein said amylin agonist analogue is <sup>25,28,29</sup>Pro-h-amylin [SEQ ID NO:1] (SEQ ID NO:1).
  
4. (Currently Amended) [[A]] The method according to claim 1 wherein said amylin or amylin agonist composition is administered subcutaneously.
  
5. (Currently Amended) [[A]] The method according to claim 4 wherein said amylin or amylin agonist composition is administered from 1 to 4 times per day.
  
6. (Currently Amended) [[A]] The method according to claim 5 wherein said amylin or amylin agonist is administered in an amount from 30 µg/dose to 300 µg/dose.
  
7. (Currently Amended) A method of treating obesity in a human subject in need thereof comprising administering to said subject an effective amount of a composition

Appl. No. 08/870,762  
Docket No.: 226/104 US  
Page 4

comprising an obesity relief agent consisting of an amylin or an amylin agonist and a pharmaceutically acceptable carrier, wherein said amount is effective to treat obesity.

8. Canceled.

9. (Currently Amended) [[A]] The method according to claim 1, 2 or 3 wherein the composition comprising an effective amount of an anti-obesity agent consisting of an amylin or amylin agonist is administered QID and contains said amylin or amylin agonist in an amount of 30 µg/dose.

10. (Currently Amended) [[A]] The method according to claim 1, 2 or 3 wherein the composition comprising an effective amount of an anti-obesity agent consisting of an amylin or amylin agonist is administered TID or QID contains said amylin or amylin agonist in an amount of 60 µg/dose.

11. (Currently Amended) [[A]] The method according to claim 1, wherein the composition comprising an effective amount of an anti-obesity agent consisting of an amylin or an amylin agonist is administered in an amount of about 0.01 milligrams per day to about 5 milligrams per day.

12. (Currently Amended) [[A]] The method according to claim 1, wherein the composition comprising an effective amount of an anti-obesity agent consisting of an amylin or amylin agonist is administered in an amount of about 0.05 milligrams per day to about 2 milligrams per day.

13. (Currently Amended) [[A]] The method according to claim 1, wherein the composition comprising an effective amount of an anti-obesity agent consisting of an amylin or

Appl. No. 08/870,762  
Docket No.: 226/104 US  
Page 5

amylin agonist is administered in an amount of about 0.1 milligrams per day to about 1 milligram per day.

14. (Currently Amended) A method of treating obesity in a human subject in need thereof comprising administering to said subject a composition comprising a compound selected from the group consisting of amyline an amylin, an amylin agonists agonist, and pharmaceutically acceptable salts thereof, wherein said compound is administered in an amount effective to treat obesity and wherein said compound is not administered in conjunction with another obesity relief agent.

15. (Currently Amended) The method of claim 1, 2 or 3, wherein the weight of said human subject is lower following reduced after four weeks of said treatment from the weight of said subject prior to said treatment.

16. (Currently Amended) A method of treating obesity in a human subject in need thereof comprising administering to said subject an effective amount of a composition consisting essentially of an amylin or an amylin agonist, wherein said amount is effective to treat obesity.

17. (New) The method of claim 7, 14 or 16, wherein said amylin agonist is  
<sup>25,28,29</sup>Pro-h-amylin (SEQ ID NO:1).